secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0000078003-23-000085
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer Q2 revenues $12.7B (-54% YoY); narrows FY revenue guidance to $67-70B
----------------------------------------------------------------------------

- Q2 reported diluted EPS $0.41 (-77% YoY); adjusted diluted EPS $0.67 (-67% YoY).
- Comirnaty and Paxlovid combined revenue $1.6B; ex-COVID revenue grew 5% operationally.
- Narrowed FY2023 revenue guidance to $67-70B (previously $67-71B); maintained adjusted EPS guidance $3.25-3.45.
- Non-COVID operational growth expectation reduced to 6-8% from 7-9% due to label, ACIP recommendation, tornado damage.
- Closed $31B debt offering to partly fund Seagen acquisition; transaction expected late 2023/early 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800323000085/0000078003-23-000085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800323000085/pfe-20230801.htm
  HTML page:      https://secwatch.observer/filing/0000078003-23-000085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer